{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T04:02:28Z","timestamp":1769832148654,"version":"3.49.0"},"reference-count":39,"publisher":"S. Karger AG","issue":"6","license":[{"start":{"date-parts":[[2014,1,1]],"date-time":"2014-01-01T00:00:00Z","timestamp":1388534400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"},{"start":{"date-parts":[[2014,1,1]],"date-time":"2014-01-01T00:00:00Z","timestamp":1388534400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Am J Nephrol"],"published-print":{"date-parts":[[2014]]},"abstract":"<b><i>Background:<\/i><\/b> Elevated serum phosphorus and FGF23 are independent cardiovascular risk factors in patients with chronic kidney disease. In a randomized controlled trial of patients with dyslipidemia assigned to either extended release niacin (ERN) alone, ERN combined with the selective prostaglandin D<sub>2<\/sub> receptor subtype 1 inhibitor laropiprant (ERN-L) or placebo, niacin lowered serum phosphorus; however, it is not known if it lowers FGF23 concentrations. <b><i>Methods:<\/i><\/b> This is an ancillary study to a multicenter, randomized, double-blind, placebo-controlled trial among patients with dyslipidemia and an estimated glomerular filtration rate (eGFR) of 30-74 ml\/min\/1.73 m<sup>2<\/sup>. Participants were randomized to ERN-L (n = 162), ERN (n = 97), or placebo (n = 68) in a 3:2:1 ratio for 24 weeks. The primary outcome was a change in serum FGF23 concentrations, and secondary outcomes were changes in other mineral metabolism parameters. <b><i>Results:<\/i><\/b> Both the ERN and ERN-L groups showed significant declines in serum phosphorus, calcium and calcium\u00b7phosphorus product at 24 weeks compared to placebo. A significant decline from baseline (10.9%, p < 0.01) in the serum FGF23 concentration was observed in the ERN group compared to placebo, but not in the ERN-L group compared to placebo (p = 0.36 and 0.97 for ERN-L and placebo, respectively), despite equivalent declines in serum phosphorus. Similarly, the most marked declines in PTH occurred in the ERN-only group versus placebo; no change in PTH was observed in the ERN-L group. <b><i>Conclusions:<\/i><\/b> In this ancillary study of hyperlipidemic patients with an eGFR of 30-74 ml\/min\/1.73 m<sup>2<\/sup>, ERN alone but not in combination with laropiprant lowered FGF23 and PTH concentrations. If confirmed, niacin may provide a novel strategy to decrease phosphorus, FGF23, and PTH concentrations in patients with chronic kidney disease.<\/jats:p>","DOI":"10.1159\/000362424","type":"journal-article","created":{"date-parts":[[2014,5,20]],"date-time":"2014-05-20T07:12:17Z","timestamp":1400569937000},"page":"484-490","source":"Crossref","is-referenced-by-count":26,"title":["Effect of Niacin on FGF23 Concentration in Chronic Kidney Disease"],"prefix":"10.1159","volume":"39","author":[{"given":"Madhumathi","family":"Rao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Steffes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew","family":"Bostom","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joachim H.","family":"Ix","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"127","published-online":{"date-parts":[[2014,5,20]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1053%2Fj.ackd.2010.12.003"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1681%2FASN.2009121293"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1038%2Fki.2012.176"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1161%2FCIRCULATIONAHA.108.844506"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1056%2FNEJMoa0706130"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016%2Fj.atherosclerosis.2009.01.001"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1681%2FASN.2010080894"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1681%2FASN.2006080936"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1681%2FASN.2012030223"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1093%2Fndt%2Fgfr144"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1093%2Fndt%2Fgfq419"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.2215%2FCJN.05420709"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.3109%2F08860221003753323"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1053%2Fj.ajkd.2009.12.015"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1007%2Fs11255-006-0001-x"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1093%2Fndt%2Fgfh781"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1093%2Fndt%2F14.5.1195"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.2215%2FCJN.04211007"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.2215%2FCJN.01470307"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1016%2Fj.jacl.2011.03.455"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.2215%2FCJN.07341009"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1053%2Fj.ajkd.2010.06.029"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1111%2Fj.1742-1241.2008.01938.x"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1016%2Fj.amjcard.2007.10.023"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1016%2FS0272-6386%2803%2900111-2"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1053%2Fj.ajkd.2010.02.337"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.7326%2F0003-4819-150-9-200905050-00006"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1016%2Fj.jacc.2012.03.040"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1053%2Fj.ajkd.2010.06.011"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1016%2Fj.plefa.2009.06.007"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1359%2Fjbmr.080228"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1016%2Fj.bone.2012.06.003"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1681%2FASN.2006070783"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1681%2FASN.2012070719"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1001%2Fjama.2011.826"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1093%2Feurjhf%2Fhfq106"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1016%2Fj.ahj.2008.05.016"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1681%2FASN.2004070602"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1161%2FCIRCULATIONAHA.105.553198"}],"container-title":["American Journal of Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/362424","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/362424","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T17:39:10Z","timestamp":1745429950000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/000362424"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014]]},"references-count":39,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2014,7,1]]},"published-print":{"date-parts":[[2014,7,4]]}},"URL":"https:\/\/doi.org\/10.1159\/000362424","archive":["Portico"],"relation":{"is-supplemented-by":[{"id-type":"doi","id":"10.6084\/m9.figshare.5126458","asserted-by":"subject"}]},"ISSN":["0250-8095","1421-9670"],"issn-type":[{"value":"0250-8095","type":"print"},{"value":"1421-9670","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014]]}}}